IXICO PLC — Board/Management Information 2014

Feb 6, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4121Z

IXICO plc

06 February 2014

6 February 2014

IXICO plc

Appointment of Joint Broker

IXICO plc (Ticker: IXI) ("IXICO" or the "Company"), the brain health company, today announces the appointment of Daniel Stewart & Company as its joint broker with immediate effect.

Enquiries

IXICO plc

+44 207 691 2064

Derek Hill, CEO

Charles Spicer, Director

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 207 418 8900

James Steel

Clare Terlouw

Daniel Stewart & Company (Joint Broker)

+44 207 776 6550

Mark Treharne

David Hart

FTI Consulting Limited (U.K. Investor and Media Relations)

+44 207 831 3113

John Dineen

Simon Conway

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and more recently launched into the wider clinical diagnostic market. Since incorporation, IXICO has been awarded contracts by eight of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPBIGDDDXGBGSU